Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial.
Saved in:
| Title: | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial. |
|---|---|
| Authors: | Capozza T; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Burkey J; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Van De Wetering J; ICON, Groningen, the Netherlands., Kerb R; ICON, Mannheim, Germany., Callahan J; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Kryzhanovskaya L; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA., Erickson M; Intercept Pharmaceuticals, Inc, Morristown, New Jersey, USA. |
| Source: | Clinical and translational science [Clin Transl Sci] 2025 May; Vol. 18 (5), pp. e70229. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
